AHA Coding Clinic® for HCPCS - 2012 Issue 2; For Your Information

Reporting Update for the Administration of PROVENGE®

On January 6, 2012, The Centers for Medicare & Medicaid Services (CMS) reissued CR 7431, Transmittal 2380, for autologous cellular immunotherapy (PROVENGE®) treatment of metastatic prostate cancer with clarification regarding reporting the administration of PROVENGE® separately. However, when CPT code 96365, Intravenous infusion, for therapy, prophylaxis or diagnosis (specify substance or drug); initial, up to 1 hour, is reported with HCPCS code Q2043, Sipuleucel-T, minimum of 50 million autologous cd54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion, an edit is caused which indicates that code 96365 is bundled with Q2043. According to...

To read the full article, sign in and subscribe to the AHA Coding Clinic® for HCPCS.

Thank you for choosing Find-A-Code, please Sign In to remove ads.